BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 26450707)

  • 1. Topical treatment of basal cell carcinoma with the immune response modifier imiquimod.
    Papakostas D; Stockfleth E
    Future Oncol; 2015 Nov; 11(22):2985-90. PubMed ID: 26450707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imiquimod and lymphatic field clearance: a new hypothesis based on a remote immune action on skin cancer.
    Akkilic-Materna M; Massone C; Komericki P
    Acta Derm Venereol; 2011 Jun; 91(4):432-5. PubMed ID: 21547348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
    Tillman DK; Carroll MT
    Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
    Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
    Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imiquimod - Its role in the treatment of cutaneous malignancies.
    Bubna AK
    Indian J Pharmacol; 2015; 47(4):354-9. PubMed ID: 26288465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New perspective in immunotherapy: local imiquimod treatment].
    Kemény L; Nagy N
    Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
    Love WE; Bernhard JD; Bordeaux JS
    Arch Dermatol; 2009 Dec; 145(12):1431-8. PubMed ID: 20026854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond a decade of 5% imiquimod topical therapy.
    A Gaspari A; Tyring SK; Rosen T
    J Drugs Dermatol; 2009 May; 8(5):467-74. PubMed ID: 19537370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
    Vidal D; Matías-Guiu X; Alomar A
    Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ophthalmic side-effects of imiquimod therapy in the management of periocular skin lesions.
    Cannon PS; O'Donnell B; Huilgol SC; Selva D
    Br J Ophthalmol; 2011 Dec; 95(12):1682-5. PubMed ID: 20702431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions.
    Wagstaff AJ; Perry CM
    Drugs; 2007; 67(15):2187-210. PubMed ID: 17927284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of imiquimod in skin cancer treatment.
    Urosevic M; Dummer R
    Am J Clin Dermatol; 2004; 5(6):453-8. PubMed ID: 15663342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma.
    Sapijaszko MJ
    Skin Therapy Lett; 2005; 10(6):2-5. PubMed ID: 16292452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Photodynamic therapy vs imiquimod].
    Serra-Guillén C; Nagore E; Guillén C
    Actas Dermosifiliogr; 2012; 103(6):488-501. PubMed ID: 22178262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical application of imiquimod for the treatment of high-risk facial basal cell carcinoma in Gorlin syndrome.
    Vereecken P; Monsieur E; Petein M; Heenen M
    J Dermatolog Treat; 2004 Apr; 15(2):120-1. PubMed ID: 15204165
    [No Abstract]   [Full Text] [Related]  

  • 16. Imiquimod 5 percent cream and the treatment of cutaneous malignancy.
    Navi D; Huntley A
    Dermatol Online J; 2004 Jul; 10(1):4. PubMed ID: 15347486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imiquimod induces sustained remission of actinic damage: a case report spanning one decade of observation.
    Knackstedt TJ; Quitadamo M
    Cutis; 2015 Feb; 95(2):E20-3. PubMed ID: 25750973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe.
    Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Tebbs V; Owens M; Stampone P
    Eur J Dermatol; 2005; 15(5):374-81. PubMed ID: 16172048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
    Huber A; Huber JD; Skinner RB; Kuwahara RT; Haque R; Amonette RA
    Dermatol Surg; 2004 Mar; 30(3):429-30. PubMed ID: 15008876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma.
    Torres A; Niemeyer A; Berkes B; Marra D; Schanbacher C; González S; Owens M; Morgan B
    Dermatol Surg; 2004 Dec; 30(12 Pt 1):1462-9. PubMed ID: 15606733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.